Exec Chat: Pear Therapeutics’ CEO Charts Future For Digital Therapeutics Following SPAC Deal

 
• By Reed Miller

Pear has commercialized FDA-cleared prescription digital therapeutics for substance abuse disorder, opioid use disorder and chronic insomnia and has 14 more in development. CEO Corey McCann explained Pear’s vision for how PDTs can transform health care.

Woman using a prescription digital therapeutic developed by Pear Therapeutics
• Source: Pear Therapeutics

More from Deals

More from Business